Ensovibep maintains potency in an in vitro assay and demonstrated full inhibition of all newly emerging known variants of concern, including the Delta variants of concern EMPATHY Phase 2/3 trial enrolling ambulatory patients in 5 countries with more countries to be added in the coming months, with

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 /  Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of

Global Phase 3 trial designed to investigate safety and efficacy of ensovibep in hospitalized adults with COVID-19 Ensovibep receives U.S. FDA Fast Track Designation for the treatment of COVID-19 in both hospitalized and ambulatory settings ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 13, 2021

Zurich-Schlieren, Switzerland, June 9, 2021.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial public offering in the United States of 3,000,000

EMPATHY global multi-center Phase 2 – 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3 Novartis has been granted

in vitro  studies show ensovibep (MP0420) maintains full potency against the known mutations of SARS-CoV-2, including those present in variants first identified in Brazil, California, India, and New York, in addition to the previously reported variants originating from the UK and South Africa

Zurich-Schlieren, Switzerland, May 04, 2021.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021.

Zurich-Schlieren, Switzerland, April 23, 2021.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has filed a registration statement on Form F-1 with the

Zurich-Schlieren, Switzerland, April 21, 2021.  At today’s AGM of  Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, the shareholders of the company approved all motions proposed by the Board of

Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting tumor escape New data show that the FAP x CD40 product candidate, MP0317, led to a localized macrophage repolarization and reversion of T-cell suppression.